GPCR vs. AGIO, EVO, GLPG, CPRX, HRMY, NAMS, SNDX, EWTX, SDGR, and SUPN
Should you be buying Structure Therapeutics stock or one of its competitors? The main competitors of Structure Therapeutics include Agios Pharmaceuticals (AGIO), Evotec (EVO), Galapagos (GLPG), Catalyst Pharmaceuticals (CPRX), Harmony Biosciences (HRMY), NewAmsterdam Pharma (NAMS), Syndax Pharmaceuticals (SNDX), Edgewise Therapeutics (EWTX), Schrödinger (SDGR), and Supernus Pharmaceuticals (SUPN). These companies are all part of the "pharmaceutical preparations" industry.
Agios Pharmaceuticals (NASDAQ:AGIO) and Structure Therapeutics (NASDAQ:GPCR) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, valuation, institutional ownership, earnings, community ranking, media sentiment, dividends, profitability and analyst recommendations.
In the previous week, Structure Therapeutics had 2 more articles in the media than Agios Pharmaceuticals. MarketBeat recorded 12 mentions for Structure Therapeutics and 10 mentions for Agios Pharmaceuticals. Agios Pharmaceuticals' average media sentiment score of 0.81 beat Structure Therapeutics' score of 0.68 indicating that Structure Therapeutics is being referred to more favorably in the news media.
Structure Therapeutics has lower revenue, but higher earnings than Agios Pharmaceuticals. Structure Therapeutics is trading at a lower price-to-earnings ratio than Agios Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Structure Therapeutics has a net margin of 0.00% compared to Structure Therapeutics' net margin of -1,199.26%. Agios Pharmaceuticals' return on equity of -32.69% beat Structure Therapeutics' return on equity.
Agios Pharmaceuticals currently has a consensus price target of $35.00, suggesting a potential upside of 6.06%. Structure Therapeutics has a consensus price target of $85.71, suggesting a potential upside of 139.29%. Given Agios Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Structure Therapeutics is more favorable than Agios Pharmaceuticals.
91.8% of Structure Therapeutics shares are owned by institutional investors. 4.2% of Agios Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Agios Pharmaceuticals received 463 more outperform votes than Structure Therapeutics when rated by MarketBeat users. However, 78.95% of users gave Structure Therapeutics an outperform vote while only 67.80% of users gave Agios Pharmaceuticals an outperform vote.
Summary
Structure Therapeutics beats Agios Pharmaceuticals on 12 of the 16 factors compared between the two stocks.
Get Structure Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for GPCR and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding GPCR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Structure Therapeutics Competitors List
Related Companies and Tools
